Suppr超能文献

美国食品药品监督管理局批准小分子药物和生物制品标签扩展中的真实世界证据

Real-World Evidence in FDA Approvals for Labeling Expansion of Small Molecules and Biologics.

作者信息

Deng Yung-Fang, Girman Cynthia J, Ritchey Mary E

机构信息

CERobs Consulting, LLC, Asheville, NC, USA.

Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

出版信息

Ther Innov Regul Sci. 2025 Jun 4. doi: 10.1007/s43441-025-00816-9.

Abstract

INTRODUCTION

Real-world evidence (RWE) can support the evaluation of safety and efficacy for medical products, but its extent of use in labeling expansion submissions remains unclear. This study aimed to characterize the RWE used in labeling expansion or likely used, as identified through literature search, for drugs and biologics.

METHODS

We identified RWE used in FDA-approved labeling expansion for drug and biologic supplemental applications from January 2022 to May 2024 (Drugs@FDA), using FDA prescribing information and review documents. We also searched ClinicalTrials.gov and PubMed to identify RWE not included in the FDA approval letter and labeling but could have been incorporated into submissions by sponsors. Characteristics of the RWE were extracted and summarized.

RESULTS

Among 218 labeling expansions granted, RWE was found in FDA documents for 3 approvals and elsewhere for 52 approvals. The proportion of approvals with RWE was 23.3%, 27.7%, and 23.7% in 2022, 2023, and 2024, respectively. RWE was most commonly found in submissions for oncology (43.6%), infection (9.1%), and dermatology (7.3%). Greater use of RWE was identified in submissions for drugs (69.1%) and to expand indications (78.2%). RWE came from 88 studies, with 48.9% addressing both safety and efficacy. Most of the RWE studies were retrospective (65.9%), employed a cohort study design (87.5%), and used electronic health records (EHR) data (75.0%).

CONCLUSION

We observed limited RWE use in granted labeling expansion, and the reason is unclear due to incomplete FDA documentation of supplemental approvals-RWE may not have been submitted, may have been submitted but determined by FDA to be of limited use, may have contributed substantively to the supplemental approval, or some combination of these across submissions. Improving accessibility and transparency in RWE's acceptability within review documents can enhance our understanding of the extent and quality of RWE used for labeling expansion.

摘要

引言

真实世界证据(RWE)可支持对医疗产品安全性和有效性的评估,但其在标签扩展申报中的使用程度仍不明确。本研究旨在描述通过文献检索确定的、用于药品和生物制品标签扩展或可能用于标签扩展的RWE的特征。

方法

我们利用美国食品药品监督管理局(FDA)的处方信息和审评文件,确定了2022年1月至2024年5月期间FDA批准的药品和生物制品补充申请中用于标签扩展的RWE(Drugs@FDA)。我们还检索了ClinicalTrials.gov和PubMed,以识别未包含在FDA批准函和标签中但可能已被申办者纳入申报材料的RWE。提取并总结了RWE的特征。

结果

在获批的218项标签扩展中,FDA文件中有3项批准使用了RWE,其他地方有52项批准使用了RWE。2022年、2023年和2024年使用RWE的批准比例分别为23.3%、27.7%和23.7%。RWE最常见于肿瘤学(43.6%)、感染(9.1%)和皮肤病学(7.3%)的申报材料中。在药品申报材料(69.1%)和用于扩展适应症的申报材料(78.2%)中发现RWE的使用更为普遍。RWE来自88项研究,其中48.9%涉及安全性和有效性。大多数RWE研究是回顾性的(65.9%),采用队列研究设计(87.5%),并使用电子健康记录(EHR)数据(75.0%)。

结论

我们观察到在获批的标签扩展中RWE的使用有限,由于FDA对补充批准的文件记录不完整,原因尚不清楚——RWE可能未被提交,可能已被提交但被FDA判定用途有限,可能对补充批准有实质性贡献,或者在不同申报材料中这些情况的某种组合。提高审评文件中RWE可接受性的可及性和透明度,可以增强我们对用于标签扩展的RWE的范围和质量的理解。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验